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1. Introduction
  The acute respiratory distress syndrome (ARDS) is 
characterized by diffuse inflammation of the lung’s 
alveolar-capillary membrane in response to various 
pulmonary and extrapulmonary insults[1]. Pulmonary injury 
is occured by directly gastric aspiration, pneumonia, 
inhalational injury, pulmonary contusion or indirectly 
sepsis, trauma, pancreatitis, multiple transfusions of blood 
products mechanisms[2].
  The pathologic features, margination of polymorphonuclear 
neutrophil leukocytes (PMNL) into the lung alveoli, 
interstitial/intraalveolar edema, perivascular and/or 
intraalveolar hemorrhage and hyaline membrane (HM) 
formation are consistent with the effects of the complex 
interaction of inflammatory mediators on alveolar epithelial 
and capillary endothelial cells[3]. ARDS are classified at 
different time as acute, subacute and chronic phases. 
In the acute phase (the first 1-6 d), there is evidence 
of interstitial and alveolar edema with accumulation of 
Objective: To investigate salbutamol effects on histopathologic features of acute respiratory 
distress syndrome (ARDS). Methods: ARDS was designed in Wistar albino male rats, 250-
300 g in weight, by intratracheal instillation of physiological saline solution. Anesthezied and 
tracheotomized rats with ARDS were pressure-controlled ventilated. At the end of the 210 
minutes, two hours past and nebulized salbutamol inhalation was tried. All rats were assigned 
to two groups: Group 1 (n=10) control group, given no treatment, group 2 (n=10) received 
salbutamol. Nebulized salbutamol inhalation was given in the dosage of 0, 15 mg/kg/dose. Rats 
were continued to be on ventilator through the experiment. After the last inhalation, two hours 
past and their both lungs were excised for histopathological examination. Results: Rat-model 
ARDS had similar histopathological appearance occuring during the acute phase of the acute 
respiratory distress syndrome in humans. A statistical difference was seen between control and 
salbutamol group (P=0.002) for HM. The margination of leukocytes was decreased in salbutamol 
group. The difference was significant (P<0.042). Hemorrhage and interstitial/intraalveolar edema 
were much lower in 0.15 mg/dose nebulized salbutamol group than that of control group. There 
was a significant difference statistically between two groups (P<0.001). Conclusions: Inhaled 
salbutamol therapy for ARDS is may be associated with the improvement of inflamation. Besides 
known effects of salbutamol, the reducing of infiltration of polymorphonuclear neutrophil 
leukocytes, interstitial/intraalveolar edema, perivascular and/or intraalveolar hemorrhage and 
hyaline membrane formation should be emphasized. 
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neutrophils, macrophages, and red blood cells in the alveoli. 
Prominent hyaline membranes is occured in the alveoli as 
well. In the subacute phase (the next 7-14 d), some of the 
edema has usually been reabsorbed, In the chronic phase 
(after 14 d), acute neutrophilic infiltration resolve with 
more mononuclear cells and alveolar macrophages in the 
alveoli[4].
  The current treatment modalities and new therapeutic 
approaches primarily focused on the resolution of pathologic 
features in ARDS. These treatments include glucocorticoids, 
surfactants, inhaled nitric oxide, antioxidants, protease 
inhibitors, and a variety of other antiinflammatory 
treatments.  Unfortunately,  to date none of these 
pharmacologic treatments has proven to be effective[5]. The 
first step toward improving of ARDS is to remove the alveolar 
edema fluid to the lung interstitium, where net clearance 
can occur through lung lymphatics and the pulmonary 
microcirculation. The resolution of edema was reported in an 
animal models with ALI[6,7]. Perkins et al demonstrated that 
intravenous salbutamol, a selective 毬2 adrenergic agonists, 
may reduce alveolar-capillary permeability, accelerate 
resolution of pulmonary edema and improve outcome in 
patients with ARDS[8]. Alveolar fluid clearance and arterial 
oxygen tension due to hydrostatic pulmonary edema were 
increased by aerosolized salmeterol[9,10].
  The migration of large numbers of neutrophils can result 
in epithelial injury. 毬2 adrenergic agonists reduce in vitro 
neutrophil adhesion to human alveolar epithelial cells[11] 
and endothelial cells[12-14]. Masclans JR et al reported that 
pulmonary sequestration of radio-labelled neutrophils was 
prevented by the treatment of 300 毺g inhaled salbutamol 
in normal human volunteers[15]. Also salbutamol is a potent 
upregulator for repairing of human alveolar endothelial 
and epithelial cells[16]. In this article, we aimed to evaluate 




  Wistar albino male rats, weighing 250-300 g, were obtained 
from the Experimental Animal Research Center, Cukurova 
University Medical Faculty. The animals were kept in a 
temperature (21 依 2) 曟 and humidity (60% 依 5%) controlled 
room in which a 12-12 h light-dark cycle was maintained. 
Animals were fed a standard rat chow diet, had access to 
water ad libitum, and were synchronized by the maintenance 
of controlled environmental conditions (light, temperature, 
feeding time, etc.) The experiments were performed in 
accordance with the guidelines for Animal Research from 
the National Institute of Health and were approved by the 
Committee on Animal Research at Cukurova University, 
Turkey.
2.2. Experimental design
  Rats were anesthezied with 1.25 mg/kg body weight xylazine 
(Rompum, Bayer, Brazil, 2% solution) and 80 mg/kg body weight 
ketamine (Ketalar, Pfizer, USA, 50 mg/mL) intraperitoneally 
and instrumented in a manner previously described by 
German and Häfner et al[17,18] A catheter was placed into 
one carotid artery for blood gas parameters,  partial arterial 
oxygen pressure (PaO2) and partial arterial carbon dioxide 
pressure (PaCO2). A tracheostomy was performed, and the 
trachea was canullated with polyethylene tubing, ID 1, 5 
mm. They were pressure-controlled ventilated (Evita 4 
Neoflow, Dräger, Germany) with 100% oxygen at a respiratory 
rate of 30 breaths/min, inspiration-expiration ratio of 1:2, 
peak inspiratory pressure of 15 cmH2O at positive end-
expiratory pressure (PEEP) of 2 cmH2O. At the starting of 
the experiment, PaO2 and PaCO2 were evaluated under 
the described ventilatory settings. Before lavage, the peak 
inspiration pressure (PIP) was raised to 28 cmH2O and PEEP 
to 8 cmH2O. Rat lung parenchyma lavage was applied with 5 
mL暳6 mL of physiological saline solution per animal every 
half an hour through 210 min. The ventilation setting was not 
changed during the whole experimental period. 
  All rats with ARDS were assigned to two groups: Group 
1 (n=10) control group, given no treatment, group 2 
(n=10) received inhalation of 0.15 mg/kg/dose salbutamol 
(Ventolin®, Glaxo Smithkline, Boronia, Au, 2.5 mg/2.5 mL 
solution for nebulization) diluted in 4 mL of saline (0.9% 
NaCl). At two hours after the last lavage, control group rats 
were sacrified. Salbutamol was given four times during a 
1 h period with a vibrating mesh nebulizer (Aeroneb Solo, 
Aerogen) placed on the ventilator. Physiological saline was 
added so that the inhalation time was 5 min. After the last 
inhalation, two hours past and rats were sacrified. Both lungs 
of all rats were excised for histopathological examination. 
2.3. Light microscopic examination
  Lung tissues were fixed in 10% neutral buffered formalin 
and was embedded in paraffin. Sections of tissue were cut at 
5 毺m, mounted on slides, stained with hematoxylin-eosin 
(H-E). The sections were examined by Olympus conventional 
CX21 light microscope. Grading was performed with respect 
to the severity of the pathological features [the margination 
and infiltration of polymorphonuclear neutrophil leukocytes 
(PMNL), interstitial/intraalveolar edema, perivascular and/
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or intraalveolar hemorrhage and hyaline membrane (HM) 
formation] as grade 0 (clear lung paranchyma), grade 1 (25% 
of lung paranchyma), grade 2 (50% of lung paranchyma), 
grade 3 (75% of lung paranchyma) and grade 4 (100% of lung 
paranchyma)[17] (Table 2). Slides were coded and evaluated 
without any knowledge of the sacrifice time. 
2.4. Electron microscopic examination
  The tissues of 1 mm3 thickness were immediately placed 
in 5% glutaraldehyde buffered at pH 7.4 with Millonig 
phosphate buffer for four hours. Samples were subsequently 
fixed in 1% osmic acid for two hours. After dehydration in 
acetone, they were embedded in araldite. Ultrathin sections 
were stained with uranyl acetate and lead citrate and were 
examined in a Jeol JEM 1400 electron microscope. 
2.5. Statistical analysis
  A computer program (SPSS 11.0) was used for statistical 
analysis. Histopathological grading were expressed as means 
依 standard deviation (SD). While differences among the 
groups were detected, group means were compared with the 
using of the Mann-Whitney U-test. A P-value <0.05 was 
considered significant.
3. Results
  At the starting of the experiment, the mean blood PaO2 and 
PaCO2 values were (350.34依75.69) and (52.16依5.89) mmHg 
before lavage, respectively. Directly after lavage (210 min 
after lavage), PaO2 decreased to (57.55依12.10) mmHg and 
PaCO2 increased to (73.27依5.60) mmHg (Table 1). The light 
microscopic examination showed that the histopathological 
variables of control group like hyaline membrane formation, 
margination of polymorphonuclear neutrophil leukocytes, 
interstitial/intraalveolar edema and perivascular and/or 
intraalveolar hemorrhage reached values similar to those of 
humans with the acute phase of ARDS (Figure 1 A,B,C,D). 
The grading of histopathological variables, median and 
means 依 standard deviation (SD) values were presented for 
control and salbutamol group in Table 2.
Figure 1. Light misroscopic examination of control group: A. 
Infiltration of polymorphonuclear neutrophil leukocytes into the 
lung alveoli (H&E×200). B. Interstitial and intraalveolar edema 
(H&E×400). C. Perivascular and/or intraalveolar hemorrhage 
(H&E×400). D. Hyaline membrane formation (H&E×200).
Table 1
Arterial blood gas parameters of control group.
 Before starting of the experiment (PaO2 / PaCO2) 210 min after lavage (PaO2 / PaCO2)
Minimum 255.40 / 40.80 35.40 / 62.70 
Maximum 515.80 / 59.60 71.20 / 78.90
Mean依Std.Deviation 350.34依75.69 / 52.16依5.89 57.55依12.10 / 73.27依5.60
Table 2
Median, Mean依SD values and scores of Hyaline membrane (HM) formation, margination and infiltration of polymorphonuclear neutrophil 
leukocytes (PMNL) into the lung alveoli, interstitial/intraalveolar edema and perivascular and/or intraalveolar hemorrhage: Grade 0 (clear lung 
paranchyma), grade 1 (25% of lung paranchyma), grade 2 (50% of lung paranchyma), grade 3 (75% of lung paranchyma) and grade 4 (100% of 
lung paranchyma) in both lung.
Groups
                                             Grading 
n Median (range) Mean依SD P value
0(right/left) 1(right/left) 2(right/left) 3(right/left) 4(right/left)
Group 1 
HM -/- -/- 2/3 5/3 3/4 10/10 3.0 3.1依0.7
PMNL -/- -/- 2/1 6/7 2/2 10/10 3.0 3.0依0.6
Edema -/- -/- 0/1 8/4 2/5 10/10 3.0 3.3依0.5
Hemorrhage -/- -/- -/- 4/5 6/5 10/10 4.0 3.5依0.5
Group 2
HM 1/1 4/3 2/2 2/3 1/1 10/10 2.0 1.9依1.2   0.002
PMNL -/- 1/1 4/3 5/5 0/1 10/10 3.0 2.5依0.8   0.042
Edema 2/3 6/4 0/3 1/0 1/0 10/10 1.0 1.1依1.0 <0.001
Hemorrhage -/- 8/7 2/3 0/0 0/0 10/10 1.0 1.2依0.4 <0.001
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Figure 2. The comparision with control and salbutamol group 
for hyaline membrane formation, interstitial/intraalveolar edema, 
margination of polymorphonuclear neutrophil leukocytes (PMNL) into 
the lung alveoli and perivascular and/or intraalveolar hemorrhage.
 
  The mean severity of margination of PMNL, interstitial/
intraalveolar edema and perivascular and/or intraalveolar 
hemorrhage were (2.5 依 0.8), (1.1 依 1.0) and (1.2 依 0.4) 
in group 2, respectively. The margination of PMNL was 
decreased in salbutamol group. The difference was 
significant (P=0.042). There was an apperant amelioration 
for interstitial/intraalveolar edema and perivascular and/
or intraalveolar hemorrhage in nebulized salbutamol group. 
Hemorrhage and interstitial/intraalveolar edema was much 
lower in nebulized salbutamol group than that of control 
group (Figure 2). The difference was statistically significant 
(P<0.001). The mean severity of hyaline membrane formation 
was decreased from 3.1 依 0.7 to 1.9 依 1.2 in 0.15 mg/kg in 
salbutamol group. We found a statistical difference between 
control and salbutamol group (P=0.002) for HM. The light 
and electron microscopic examination of salbutamol and 
control group were shown in Figure 3 and 4, respectively. 
Figure 3. Light misroscopic examination of salbutamol group: A 
(H&E×100) and B (H&E×400). The decreasing of hyaline membrane 
formation, interstitial and intraalveolar edema, infiltration of 
polymorphonuclear neutrophil leukocytes into the lung alveoli and 
perivascular and/or intraalveolar hemorrhage were depicted.
 
Figure 4. EM examination. A. Control group: Granular dens 
stractures (black arrow). Thick basal lamina on blood-air barrier area 
(white arrow) and increased intracytoplasmic vacualization of type 
II pneumocyte (thick white arrow). Salbutamol group: B. Destroyed 
alveolar wall integrity (white arrow), erythrocytes in alveolar space 
(A), dense granules (black arrow), alveolar macrophage (AM) next 
to the alveolar wall. C. A normal Type II pneumocyte.  Microvilli 
(Mv), secretory vesicules (white arrow), mitocondrium (M), granular 
endoplasmic reticulum (GER) and nucleus were seen.
4. Discussion
  The potential benefits of 毬-adrenergic stimulation in 
acute lung injury include epithelial protection, decreased 
neutrophil chemotaxis and activation, lower proinflammatory 
cytokine production, increased surfactant secretion, 
improved respiratory mechanics, and increased alveolar fluid 
clearance[19-21]. The present study sought to identify whether 
salbutamol was having an effect on the lung pathology of 
ARDS included infiltration of polymorphonuclear neutrophil 
leukocytes into the lung alveoli, interstitial/intraalveolar 
edema, perivascular and/or intraalveolar hemorrhage and 
hyaline membrane formation.
  It is well documented that increased neutrophil 
accumulation and inflammation caused to alveolar-capillary 
permeability in the alveolar space. Data from previous 
clinical studies by using of salbutamol was attributable to 
prevention of leukocyte infiltration and chemotaxis[15,20]. 
Although the infiltration of polymorphonuclear neutrophil 
leukocytes into the lung alveoli was slightly decreassed 
after using of salbutamol in our study, the difference was 
significant between the salbutamol and control group. This 
result was compatible with previous literatures. Nebulized 
salbutamol inhalation in ARDS that had possible anti-
inflammatory effects was addressed in former studies. 
Roca et al pointed that salbutamol inhalation might play a 
role in preventing the lipid peroxidation that occurs in ALI 
and ARDS patients[24]. Also different author clarified that 
salbutamol was a potent upregulator for repairing of human 
alveolar endothelial and epithelial cells[16]. In the present 
study, we could not examined the anti-inflammatory effect 
of salbutamol by proinflammatory cytokines investigation 
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because of our laboratory limitation.
 Previous studies stated that injured epithelial alveolar 
barrier in ARDS causes to intraalveolar edema. Besides 
known effects of salbutamol, 毬2 agonists have a important 
role in alveolar fluid clearance[4]. Decreased interstitial 
and intraalveolar edema were seen in our study. There 
was distinctive reduction of edema in the intralveolar 
area compare to the group given any treatment. Nebulized 
salbutamol could improve alveolar fluid clearance without 
adversely impacting systemic hemodynamics[19,23]. In 
Perkin’s study, reduced alveolar-capillary permeability was 
shown after using of intravenous salbutamol in patients with 
ARDS[8]. Our histopathological findings were complying with 
recent literatures.
  Intraalveolar hemorrhage may have a positive impact on 
inflammation in ARDS and may have clinical implications[8]. 
We found that perivascular and/or intraalveolar hemorrhage 
after administration of 0.15 mg/kg/dose of nebulized 
salbutamol were considerably lower than those control 
group. Therefore the optimal treatment effect of 0.15 mg/kg/
dose nebulized salbutamol inhalation in four cycle with 15 
min breaks could be helpful to decrease the hemorrhage of 
lung paranchyma during the management of ARDS in the 
critical care medicine. Even though the exact mechanism 
of decreased perivascular and/or intraalveolar hemorrhage 
could not be explain clearly in the present study, it might be 
attributable to reduced of alveolar-capillary permeability 
occured by salbutamol. In this setting, these data support the 
need for controlled clinical trials of the efficacy of inhaled 
nebulized salbutamol therapy in critically ill patients with 
ARDS.
  Decreased surfactant production followed by diffuse 
epithelial damaged of alveoli resulted in hyaline membrane 
formation. We found that rats inhaled with salbutamol had 
less hyaline membrane formation than that of control group. 
Surfactant, a complex of lipids and proteins, reduces alveolar 
surface tension, has antibacterial properties, and prevents 
pulmonary edema formation. In one study, it was shown 
that the beta agonists, terbutaline and salmeterol, increased 
surfactant secretion by adult and fetal type II cells[22]. The 
mechanism of salbutamol on surfactant secretion can be 
attributed to its anti-inflammatory properties on the alveolar 
epithelium.
  It is well known that nebulized salbutamol treatment is 
standard for asthma exacerbation in hospital emergency 
wards, and a dosage regimen of 0.15 mg/kg is widely used 
and recommended[25]. Nebulized salbutamol dose with 0.15 
mg/body weight (kg) was decided based on describing in 
accordance with the Expert Panel Report 3[26]. We used a 
standard dose of 0.15 mg/kg/dose of nebulized salbutamol in 
every 15 min through one hour. Di Berardino et al presented 
that the duration of salbutamol inhalation as 30 min which 
is widely accepted for nebulization was found more useful 
for the management of patients with asthma[27]. Although no 
previous studies stated the duration of salbutamol inhalation 
in ARDS, we demonstrated that the histopathological 
findings were getting better with the duration of salbutamol 
inhalation mentioned above. 
  Our study had some limitations. First, respiratory 
mechanics could not be studied. Despite this, the aim of 
our study was primarily to assess the salbutamol effect with 
histopathologic examination in rats with ARDS. Second, 
as mention above, anti-inflammatory cytokin study could 
not be performed because of our insufficient laboratory 
facilities.
  Besides known effects of salbutamol, it should be 
emphasized that nebulized salbutamol inhalation can be 
effective in the reducing of polymorphonuclear neutrophil 
leukocytes infiltration into the lung alveoli, interstitial 
and intraalveolar edema, perivascular and/or intraalveolar 
hemorrhage and hyaline membrane formation in ARDS. The 
present study supported recent suggestions that inhaled 
salbutamol therapy could be associated with a more rapid 
improvement of inflamation in ARDS. Therefore salbutamol 
could potentially increase the quality of life in terms of 
decreasing the duration of mechanical ventilation and 
hospitalization in critically ill patients with ARDS. 
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